Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital and Alfa eCare in connection with the acquisition of Selfpoint
Mandate

Vinge advises Main Capital and Alfa eCare in connection with the acquisition of Selfpoint

January 02, 2023 Employment and Benefits Corporate Commercial M&A IT, Telecommunications and Outsourcing Intellectual Property Life Sciences & Health

The Alfa eCare group is a recognized and rapidly growing software provider within the e-health sector that offers solutions to both private and public healthcare providers in the Nordics.

Selfpoint Sverige AB was founded in 2015 and provides a comprehensive low-code platform for workflow and process management solutions for the Swedish welfare market. The company serves over 40 customers with a strong presence in the public sector. The flexible low-code platform enables customers to digitize workflows and processes across the value chain towards citizens and care givers. The acquisition of Selfpoint is the seventh acquisition by the Alfa eCare group since Main Capital became majority owners of the group in 2020.

Vinge’s team advising Main Capital and Alfa eCare mainly consisted of Filip Öhrner, Per Kling, Robin Fagerström (M&A), Sara Passandideh (Employment), Martin Boström (Commercial Agreements) Lisa Hörnqvist (IT and GDPR), Rebecka Målquist, Johan Gavelin (IP) and Emelie Schoning (project assistant).

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026